首页> 外文期刊>Toxicon: An International Journal Devoted to the Exchange of Knowledge on the Poisons Derived from Animals, Plants and Microorganisms >CNS and anticonvulsant activity of a non-protein toxin (KC-MMTx) isolated from King Cobra (Ophiophagus hannah) venom
【24h】

CNS and anticonvulsant activity of a non-protein toxin (KC-MMTx) isolated from King Cobra (Ophiophagus hannah) venom

机译:中枢神经系统和从眼镜王蛇(Ophiophagus hannah)毒液中分离出的非蛋白毒素(KC-MMTx)的抗惊厥活性

获取原文
获取原文并翻译 | 示例
       

摘要

In the present study, King Cobra (Ophiophagus hannah) venom was subjected to TLC followed by column chromatography/HPLC to isolate and purify a non-protein toxin designated as KC-MMTx. (1)H NMR, IR and EIMS studies showed KC-MMTx likely to be a 282 D unsaturated aliphatic acid having molecular formula C18H34O2. The minimum lethal dose of KC-MMTx was 200 microg/kg (i.v.) and 350 microg/kg (i.p.) in Swiss albino male mice. It significantly increased pentobarbitone induced sleeping time and significantly decreased the body temperature of male albino mice. It provided protection against amphetamine aggregate toxicity in mice but failed to protect amphetamine stereotypy in male albino rats. KC-MMTx provided significant protection against drug (strychnine, pentylenetetrazole, yohimbine) induced convulsions in male albino mice. It increased serum Na+ and decreased serum Ca2+ significantly in male mice. MAO activity and brain neurotransmitter levels in male mice were altered significantly. Further detailed study is warranted on the CNS, anticonvulsant potential of KC-MMTx, which may lead to the development of newer therapeutic tools in the near future.
机译:在本研究中,对眼镜王蛇(Ophiophagus hannah)毒液进行TLC,然后进行柱色谱/ HPLC分离和纯化称为KC-MMTx的非蛋白质毒素。 (1)H NMR,IR和EIMS研究表明,KC-MMTx很可能是分子式为C18H34O2的282 D不饱和脂肪酸。在瑞士的白化病雄性小鼠中,KC-MMTx的最小致死剂量为200微克/千克(i.v.)和350微克/千克(i.p.)。它显着增加戊巴比妥诱导的睡眠时间,并显着降低雄性白化病小鼠的体温。它提供了抗苯丙胺对小鼠的总毒性的保护作用,但未能保护雄性白化病大鼠中的苯丙胺定型作用。 KC-MMTx对雄性白化病小鼠的药物引起的惊厥提供了显着的保护作用,其中所述药物包括司令宁,戊四氮,育亨宾。它在雄性小鼠中显着增加血清Na +并降低血清Ca2 +。雄性小鼠的MAO活性和脑神经递质水平发生了显着变化。有必要对CNS,KC-MMTx的抗惊厥潜力进行更详细的研究,这可能会导致在不久的将来开发更新的治疗工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号